MedTrace Logo

Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT07156253 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-09-05

No results posted yet for this study

Summary

This interventional study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SYN818 with Olaparib in adult patients with locally advanced or metastatic solid tumors

Conditions

Interventions

DRUG

SYN818 and Olaparib will be administered

Patients will orally receive SYN818 and Olaparib

Sponsors & Collaborators

  • Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-26
Primary Completion
2028-08-25
Completion
2029-02-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07156253 on ClinicalTrials.gov